Granulocyte-macrophage colony stimulating factor prior to chemotherapy for advanced epithelial ovarian cancer.
Guner
H
H
Department of Obstetrics and Gynecology, Gazi University School of Medicine, Ankara, Turkey.
Oktem
M
M
Dilek
T U K
TU
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007279:Injections, Subcutaneous; D008875:Middle Aged; D009367:Neoplasm Staging; D009503:Neutropenia / Q000517:prevention & control; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D011336:Probability; D011379:Prognosis; D011446:Prospective Studies; D018570:Risk Assessment; D018709:Statistics, Nonparametric; D016019:Survival Analysis; D016896:Treatment Outcome
D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D017239:Paclitaxel; D002945:Cisplatin